+ A
A -
dpa
Berlin
The setback suffered by German-based biotechnology company CureVac in its quest for a coronavirus vaccine will not impact either the German or the European Union vaccination campaigns, the authorities said on Thursday.
A spokesman for the German Health Ministry said in Berlin that the statement from CureVac issued on Wednesday would not affect the vaccination campaign in Germany.
And in Brussels, a spokesman for the European Commission said the news from the company did not pose any threat to the target of vaccinating 70 per cent of the bloc’s adult population by the end of July.
“From the outset, we have made use of a broad portfolio of vaccines,” the spokesman said. This had been done in order to cater for the eventuality that a vaccine could fail.
The German government also plans to retain its stake of 16 percent in the company, acquired through the KfW development bank last year at a cost of 300 million euros ($358 million).
Pharmaceutical giant Bayer said from its Leverkusen headquarters on Thursday that it planned to continue its cooperation with Tuebingen-based CureVac. The two companies concluded an agreement at the start of the year, with Bayer to provide assistance with development and logistics.
Berlin
The setback suffered by German-based biotechnology company CureVac in its quest for a coronavirus vaccine will not impact either the German or the European Union vaccination campaigns, the authorities said on Thursday.
A spokesman for the German Health Ministry said in Berlin that the statement from CureVac issued on Wednesday would not affect the vaccination campaign in Germany.
And in Brussels, a spokesman for the European Commission said the news from the company did not pose any threat to the target of vaccinating 70 per cent of the bloc’s adult population by the end of July.
“From the outset, we have made use of a broad portfolio of vaccines,” the spokesman said. This had been done in order to cater for the eventuality that a vaccine could fail.
The German government also plans to retain its stake of 16 percent in the company, acquired through the KfW development bank last year at a cost of 300 million euros ($358 million).
Pharmaceutical giant Bayer said from its Leverkusen headquarters on Thursday that it planned to continue its cooperation with Tuebingen-based CureVac. The two companies concluded an agreement at the start of the year, with Bayer to provide assistance with development and logistics.
